Stay updated on Pembrolizumab Maintenance in sNSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Maintenance in sNSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Maintenance in sNSCLC Clinical Trial page
- Check2 days agoChange DetectedThe clinical trial record for the pembrolizumab maintenance study is displayed, including its termination after enrolling 41 participants and details about the study plan, eligibility, and measured outcomes.SummaryDifference44%

- Check9 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check16 days agoChange DetectedA banner announces an NIH website transition and links to updates and FAQs, noting that NIH content may use “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check23 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check30 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check44 days agoChange DetectedThe page now shows a 403 Forbidden error HTML block, indicating restricted access to the study record rather than substantive content or updates.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Maintenance in sNSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in sNSCLC Clinical Trial page.